Funded studies
Since the establishment of the Foundation in 2015, a total of 58 applications approved which we have supported financially.
On this page there is a selection of these studies to give you an idea of which studies are running or have already been completed.
Current studies
Researcher's name: Nigel Kooreman
Study summary:
Pluripotent stem cell-derived cancer stem cells as a basis for vaccination against pancreatic cancer
Start: 2026
End: 2028
Pluripotent stem cell-derived cancer stem cells as a basis for vaccination against pancreatic cancer
Start: 2026
End: 2028
Researcher's name: Judith de Fox
Short description study:
REACTIVe-3 study: A phase 1-2 study investigating the improvement of progression-free survival by a combination of dendritic cell therapy pulsed with allogeneic tumourlysate (MesoPher) plus a CD40 agonist plus gemcitabine after FOLFIRINOX in metastatic pancreatic cancer.
Start: 2026
End: 2029
REACTIVe-3 study: A phase 1-2 study investigating the improvement of progression-free survival by a combination of dendritic cell therapy pulsed with allogeneic tumourlysate (MesoPher) plus a CD40 agonist plus gemcitabine after FOLFIRINOX in metastatic pancreatic cancer.
Start: 2026
End: 2029
Researcher's name: Dr Nadine Pronk - van Montfoort, Dr Gabri van der Pluijm
Short description study:
Therapeutics targeting of neuroimmune checkpoints to unleash the full potential of oncologytics virotherapy in pancreatic and prostate cancer
Start: 2025
End: 2027
Therapeutics targeting of neuroimmune checkpoints to unleash the full potential of oncologytics virotherapy in pancreatic and prostate cancer
Start: 2025
End: 2027
Researcher's name: Dr Marjolein Homs
Short description study:
The DURIPANC study is for patients with metastatic pancreatic cancer. Patients may participate if they have had at least 8 courses of chemotherapy with stable disease or reduction of disease. Then they start with a combination of two types of immunotherapy.
Start: 2025
End: 2027
The DURIPANC study is for patients with metastatic pancreatic cancer. Patients may participate if they have had at least 8 courses of chemotherapy with stable disease or reduction of disease. Then they start with a combination of two types of immunotherapy.
Start: 2025
End: 2027
Research Name: PREOPANC-5
Project Manager: Casper van Eijck (Jr.)
Project Manager: Casper van Eijck (Jr.)
Short description study:
Immunomonitoring in the PREOPANC-5 study: Neoadjuvant triple treatment with Folfirinox plus pembrolizimac and SRRT in patients with borderline resectable pancreatic cancer
Start: 2024
Immunomonitoring in the PREOPANC-5 study: Neoadjuvant triple treatment with Folfirinox plus pembrolizimac and SRRT in patients with borderline resectable pancreatic cancer
Start: 2024
Research Name: Objective 1, 2 and 3
Project Manager: Dr Bernadette van den Hoogen
Project Manager: Dr Bernadette van den Hoogen
Short description study:
Pre-clinical studies in syngenic orthopaedic murine model on safety and efficacy of oncolytic NDV in preparation of clinical trials to treat patients suffering from pancreatic cancer
Start: 2024
Pre-clinical studies in syngenic orthopaedic murine model on safety and efficacy of oncolytic NDV in preparation of clinical trials to treat patients suffering from pancreatic cancer
Start: 2024
Researcher's name: Prof. Dr Thorbald van Hall, Prof. Dr Alfred Vertegaal
Short description study:
Enhancing the efficacy of PDAC immunotherapy by blocking ubiquitination
Start: 2023
End: 2026
Enhancing the efficacy of PDAC immunotherapy by blocking ubiquitination
Start: 2023
End: 2026
Researcher's name: Dr Nadine Pronk - van Montfoort, Priscilla Kinderman
Short description study:
The impact of pre-existing immunity on the efficacy of reovirus-based immunotherapy
Start: 2022
End: 2026
The impact of pre-existing immunity on the efficacy of reovirus-based immunotherapy
Start: 2022
End: 2026
Completed studies
| Researchers' names | Short description of research | Start | Completed | Details |
|---|---|---|---|---|
| Drs.Freek van Otland | REACTIVe-2 trial, Dendritic cell therapy for pancreatic cancer, 18 patients | 2022 | 2024 | View |
| Dr Vera Kemp | The impact of stromal cancer associated fibroblasts and oncolytic virotherapy efficacy in pancreatic cancer (expansion of 21.02) | 2022 | 2025 | |
| Dr Martine Lamfers | Extension application to the project: Validation of tools to predict OV efficacy and design strategies to improve oncolytic virus therapy | 2022 | 2023 | |
| Dr Aida Farshadi, Dr Vera Kemp | The impact of stromal cancer associated fibroblasts and oncolytic virotherapy efficacy in pancreatic cancer | 2021 | 2025 | |
| Farzana Mohamad | Primary cell culture of immune cell and cancer organoids from pancreatic cancer patients | 2021 | 2025 | |
| Jeroen de Vrij | Adenosomes improved release of oncolytic adenovirus to cancer cells by packing in exosomes | 2021 | 2023 | |
| Drs.Freek van Rüt Land, Miranda Moski, Dr. Judith Verhagen | Safety and efficacy of the addition of IMM-101 to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients (LAPC-2 trial) | 2020 | 2023 | |
| Marko Huberts, Lisette Vogelsang, Trisha Kers, Maaike van der Mark, Thijs Janssen, Geertje van der Horst, Dr Bernadette van den Hoogen, Prof. | STRATE-VIR: developing tools to predict the effectiveness of oncolytic viruses and support personalised treatment for patients with aggressive cancer | 2020 | 2024 | |
| Drs Willem de Koning, Dana Mustafa | Pancreatic cancer bioinformatics | 2019 | 2023 | |
| Reuben van den Oever | OV therapy in immunocompetent mouse tumour models | 2019 | 2022 | |
| Dr Eveline Vietsch | Appendix-derived pancreatic cancer-reactive T lymphocytes (APART) | 2019 | 2022 | View |
| Drs. Rute Pedrosa | Metastasis of pancreatic cancer | 2019 | 2022 | View |
| Dr Aida Farshadi | 3D Organoids: A research model on the interaction between tumour and immune cells in pancreatic cancer patients | 2019 | 2022 | View |
| Dr Hosein Aziz | Study of molecular mechanisms involved in long survival of pancreatic cancer patients | 2019 | 2021 | View |
| Jasper Dumas | Processing and storing blood samples of pancreatic cancer patients | 2019 | 2021 | View |
| Marjan van de Merbel | Uncolytic viro-immuno therapy for urological tumours | 2019 | 2021 | View |
| Fleur van der Sijde | Predicting response to FOLFIRINOX chemotherapy with immune system genes | 2019 | 2021 | View |
| Eftychia Stavrakaki | Developing tools to predict and personalise the effectiveness of oncolytic viruses in the future | 2018 | 2022 | View |
| Dana Mustafa | Tumour Immuno-Pathology (TIP) Laboratory | 2017 | 2022 | View |
| Astrid Oostvogels | Immune profile in blood of pancreatic cancer patients | 2017 | 2021 | View |
| Sai ping Lau | REACTIVe-1, Dendritic cell therapy for pancreatic cancer | 2017 | 2021 | View |
| Dr Selas Bots | New adenovirus and reovirus variants for use in oncolytic virus therapy | 2017 | 2021 | View |
| Dr Diba Latifi | Immune profiles in blood of pancreatic cancer patients: clinical implementation and implementation | 2016 | 2018 | View |
| Frederique de Graaf, Dr Bernadette van den Hoogen | Development of viro-immuno-therapy with Newcastle Disease virus for treatment of patients with pancreatic cancer | 2016 | 2020 | |
| Amber Blaauboer | Increasing gemcitabine response in pancreatic cancer | 2016 | 2020 | |
| Priscilla Kinderman | Oncolytic virus therapy in immunocompetent mouse tumour models | 2016 | 2021 | View |
Financial support for research infrastructure
Name: Infrastructure for immune monitoring 2023, 2024, 2025 and 2026
Project Manager: Prof. Dr. Joachim Aerts
Short description: Tumour immunology laboratory and supervision of clinical studies
Start: 2023 (rolling)